Question special

The promise of any new therapy that can reduce COPD exacerbations is likely to have a large impact on many of our patients. Do you have a hypothesis as to why patients treated with mepolizumab in these trials had fewer annual moderate or severe exacerbations (the primary outcome), but there was no difference in patient-reported symptoms or health-related quality of life?